Does the HPV vaccination programme have implications for cervical screening programmes in the UK?

Vaccine

Volumn 32, Issue 16, 2014, Pages 1828-1833

  Beer, Helen ^a   Hibbitts, Sam ^b   Brophy, Sinead ^c   Rahman, M A ^c   Waller, Jo ^d   Paranjothy, Shantini ^b,c  

^a PUBLIC HEALTH WALES   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c SWANSEA UNIVERSITY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; CHILD; CONTROLLED STUDY; FEMALE; GESTATIONAL AGE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; PAPILLOMA; PRIORITY JOURNAL; RESIDENTIAL AREA; SCHOOL CHILD; SOCIAL ISOLATION; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION;

ADULT; FEMALE; HEALTHCARE DISPARITIES; HUMANS; IMMUNIZATION PROGRAMS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; WALES; YOUNG ADULT;

EID: 84895884901     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.087     Document Type: Article

References (24)

1. La Torre G., de Waure C., Chiaradia G., Mannocci A., Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine 2007, 25(50):8352-8358.
2. Roteli-Martins C.M., Naud P., De Borba P., Teixeira J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccines Immunother 2012, 8(3):390-397.
3. Schwarz T.F., Huang L.M., Medina D.M., Valencia A., Lin T.Y., Behre U., et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health 2012, 50(2):187-194.
4. Schwarz T.F., Spaczynski M., Schneider A., Wysocki J., Galaj A., Schulze K., et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccines 2011, 7(9):958-965.
5. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccines 2011, 7(12):1343-1358.
6. Kreimer A.R., Gonzalez P., Katki H.A., Porras C., Schiffman M., Rodriguez A.C., et al. Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica vaccine trial. Lancet Oncol 2011, 12(9):862-870.
7. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):100-110.
8. Olsson S.E., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccines 2009, 5(10):696-704.
9. Rambout L. High efficacy of HPV 16/18 AS04-adjuvanted vaccine shown against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types. Evid Based Med 2010, 15(1):7-8.
10. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccines 2011, 7(12):1359-1373.
11. Joura E.A., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., Hernandez-Avila M., et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008, 26(52):6844-6851.
12. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 25(374):9686-30114.
13. Szarewski A., Poppe W.A., Skinner S.R., Wheeler C.M., Paavonen J., Naud P., et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012, 131(1):106-116.
14. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28(38):6247-6255.
15. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105(1):28-37.
16. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13(1):89-99.
17. Lyons R.A., Jones K.H., John G., Brooks C.J., Verplancke J.P., Ford D.V., et al. The SAIL databank: linking multiple health and social care datasets. BMC Med Inf Decis Making 2009, 9:3.
18. Public Health Wales. Cervical Screening Wales 2013 [Available from: http://www.screeningservices.org/csw/prof/index.asp].
19. Government WA. Births in Wales 2007: Data from the National Community Child Health Database. 2008 [cited; Available from: www.wales.gov.uk/docs/statistics/2008/080626sdr92en.pdf].
20. Townsend P., Phillimore P., Beattie A. Health and deprivation: inequality and the North 1988.
21. Public Health Wales Vaccine uptake in children in Wales July to September 2012 2012, The National Public Health Service for Wales.
22. Public Health Wales Vaccine uptake in children in Wales July to September 2010 2010, Public Health Wales, Cardiff. 96th ed.
23. Bowyer H.L., Marlow L.A., Hibbitts S., Pollock K.G., Waller J. Knowledge and awareness of HPV and the HPV vaccine among young women in the first routinely vaccinated cohort in England. Vaccine 2013, 31(7):1051-1056.
24. Cheng E.M., Atkinson P.M., Shahani A.K. Elucidating the spatially varying relation between cervical cancer and socio-economic conditions in England. Int J Health Geogr 2011, 10:51.